Home・Elenco Azioni・Organon & Co

Organon & Co

Chiusa

SettoreSettore sanitario

13.73 0.07

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.7

Massimo

13.73

Metriche Chiave
By Trading Economics
Entrata	-292M -146M
Vendite	98M 1.6B
P/E Media del settore	17.539 55.725
EPS	0.8
Rendimento da dividendi	0.58
Margine di Profitto	-9.355
Dipendenti	10,000
EBITDA	-38M 371M

Dividendi
By Acuity
Rendimento da dividendi Media del settore	0.58% 2.25%
Utili prossimi	9 nov 2026
Prossima data del Dividendo	10 dic 2026
Prossima data del' Ex Dividendo	19 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	42M 3.6B
Apertura precedente	13.66
Chiusura precedente	13.73

Notizie sul Sentiment di mercato

By Acuity

34%

66%

63 / 339 Classifica in Healthcare

Organon & Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 set 2026, 19:25 UTC

Organon & Co is trading slightly higher, maintaining a routine pattern as it approaches the upper end of its one-month price range.

22 set 2026, 22:01 UTC

Organon & Co is seeing a decline in after-market trading, now near the lower end of its one-month trading range since Tuesday's close.

18 set 2026, 19:16 UTC

Organon & Co is trading roughly flat, showing little change since Thursday's close and remaining near the lower end of its one-month range.

17 set 2026, 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

15 set 2026, 19:56 UTC

Event

Organon & Co expects PDUFA action in Q2 2027, shares trading higher since Monday's close. The stock remains near the lower end of its one-month range.

2 set 2026, 20:08 UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

1 set 2026, 23:01 UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

28 ago 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

27 ago 2026, 23:01 UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

25 ago 2026, 19:36 UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

24 ago 2026, 23:02 UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

21 ago 2026, 23:41 UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

20 ago 2026, 22:01 UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

19 ago 2026, 23:01 UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

18 ago 2026, 23:51 UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

14 ago 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

13 ago 2026, 23:11 UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

7 ago 2026, 20:06 UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

6 ago 2026, 23:11 UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Organon & Co Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a Organon & Co - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

63 / 339 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.